Literature DB >> 24127930

Catechol-O-methyltransferase genotype modulates opioid release in decision circuitry.

Jennifer M Mitchell1, James P O'Neil, William J Jagust, Howard L Fields.   

Abstract

Impulsivity, a risk factor for substance abuse disorders, is modulated by the Val158 variant of the catechol-O-methyltransferase (COMT) gene. Rodent studies have shown that opioids enhance impulsivity. Furthermore, alcohol consumption leads to endogenous opioid release in the cortex and nucleus accumbens (NAc), and this opioid release is correlated with greater positive hedonic effect. Using the selective mu opioid receptor radioligand [¹¹C] carfentanil, we find that, following alcohol consumption, individuals with the COMT Val158 allele have greater opioid release in the right NAc but less release in medial orbital frontal cortex (OFC). These data suggest that genetic regulation of dopamine levels can affect alcohol consumption in part by modulating endogenous opioid release in specific brain regions implicated in reward, which in turn promotes impulsive choice.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  alcohol; dopamine; impulsivity; mu opioid receptor; positron emission tomography

Mesh:

Substances:

Year:  2013        PMID: 24127930      PMCID: PMC5350883          DOI: 10.1111/cts.12075

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  26 in total

1.  Separate neural systems value immediate and delayed monetary rewards.

Authors:  Samuel M McClure; David I Laibson; George Loewenstein; Jonathan D Cohen
Journal:  Science       Date:  2004-10-15       Impact factor: 47.728

2.  Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls.

Authors:  Jennifer M Mitchell; Venessa C Tavares; Howard L Fields; Mark D'Esposito; Charlotte A Boettiger
Journal:  Neuropsychopharmacology       Date:  2006-10-18       Impact factor: 7.853

3.  Impact of the COMT Val(108/158)Met polymorphism on the mu-opioid receptor system in the human brain: mu-opioid receptor, met-enkephalin and beta-endorphin expression.

Authors:  Markus C Kowarik; Julia Einhäuser; Burkard Jochim; Andreas Büttner; Thomas R Tölle; Matthias Riemenschneider; Stefan Platzer; Achim Berthele
Journal:  Neurosci Lett       Date:  2011-11-10       Impact factor: 3.046

4.  The orbital and medial prefrontal circuit through the primate basal ganglia.

Authors:  S N Haber; K Kunishio; M Mizobuchi; E Lynd-Balta
Journal:  J Neurosci       Date:  1995-07       Impact factor: 6.167

5.  Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum.

Authors:  O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

6.  Dopamine, corticostriatal connectivity, and intertemporal choice.

Authors:  Andrew S Kayser; Daicia C Allen; Ana Navarro-Cebrian; Jennifer M Mitchell; Howard L Fields
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

7.  COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.

Authors:  Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

8.  Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype.

Authors:  Charlotte A Boettiger; Jennifer M Mitchell; Venessa C Tavares; Margaret Robertson; Geoff Joslyn; Mark D'Esposito; Howard L Fields
Journal:  J Neurosci       Date:  2007-12-26       Impact factor: 6.167

9.  Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.

Authors:  Stella G Giakoumaki; Panos Roussos; Panos Bitsios
Journal:  Neuropsychopharmacology       Date:  2008-06-04       Impact factor: 7.853

10.  Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network.

Authors:  Charlotte A Boettiger; Elizabeth A Kelley; Jennifer M Mitchell; Mark D'Esposito; Howard L Fields
Journal:  Pharmacol Biochem Behav       Date:  2009-02-28       Impact factor: 3.533

View more
  6 in total

1.  The Cerebellar GABAAR System as a Potential Target for Treating Alcohol Use Disorder.

Authors:  David J Rossi; Ben D Richardson
Journal:  Handb Exp Pharmacol       Date:  2018

2.  Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.

Authors:  Kathryn T Hall; Joseph Loscalzo; Ted J Kaptchuk
Journal:  Pharmacogenomics       Date:  2019-05       Impact factor: 2.533

Review 3.  Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.

Authors:  Lloyd D Fricker; Elyssa B Margolis; Ivone Gomes; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

Review 4.  Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Authors:  Michael Samuel; Maria Rodriguez-Oroz; Angelo Antonini; Jonathan M Brotchie; Kallol Ray Chaudhuri; Richard G Brown; Wendy R Galpern; Melissa J Nirenberg; Michael S Okun; Anthony E Lang
Journal:  Mov Disord       Date:  2015-01-21       Impact factor: 10.338

5.  Challenges and new opportunities for detecting endogenous opioid peptides in reward.

Authors:  Sineadh M Conway; Marwa O Mikati; Ream Al-Hasani
Journal:  Addict Neurosci       Date:  2022-04-03

Review 6.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.